| Overview |
| bs-15514R-Cy5 |
| Ephrin A1 Receptor Polyclonal Antibody, Cy5 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Pig, Horse, Rabbit |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Ephrin A1 Receptor |
| 51-150/976 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 2041 |
| P21709 |
| Cell membrane |
| EPHA1_HUMAN; Ephrin type-A receptor 1; hEpha1; EPH tyrosine kinase; EPH tyrosine kinase 1; Erythropoietin-producing hepatoma receptor; Tyrosine-protein kinase receptor EPH. |
| This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene is expressed in some human cancer cell lines and has been implicated in carcinogenesis. [provided by RefSeq, Jul 2008]. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz